SCHEMBL10127797

SCHEMBL10127797

CN1CCC(N(C)C2CCN(c3cccc(N)c3)CC2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2C P18825 2/20 0.64
ALDH1A1 P00352 4/20 0.45
VCP P55072 4/20 0.41
AGXT P21549 1/20 0.40
HTR2A P28223 4/20 0.40
HTR2C P28335 4/20 0.40
MAPT P10636 4/20 0.40
KDM4E B2RXH2 3/20 0.40
KMT2A Q03164 2/20 0.40
GAA P10253 2/20 0.40
PTK2B Q14289 2/20 0.40
GFER P55789 1/20 0.40
ESR2 Q92731 1/20 0.40
MEN1 O00255 1/20 0.39
ALOX15 P16050 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
RECQL P46063 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3440424 0.84 ADRA2C (0.57) ADRA2CALDH1A1MAPTKDM4EKMT2A
SCHEMBL448110 0.79 ADRA2C (1.00) ADRA2CALDH1A1AGXTMAPTKDM4E
SCHEMBL16675693 0.79 ADRA2C (0.50) ADRA2CALDH1A1MAPTKDM4EKMT2A
SCHEMBL12027635 0.79 ADRA2C (0.50) ADRA2CALDH1A1MAPTKDM4EKMT2A
SCHEMBL10127786 0.79 MAPT (0.52) ALDH1A1HTR2CMAPTKDM4EKMT2A
SCHEMBL328244 0.78 ADRA2C (0.71) ADRA2CALDH1A1VCPAGXTMAPT
Hydrochloric Acid SCHEMBL16209754 0.77 ADRA2C (0.96) ADRA2CALDH1A1AGXTMAPTKDM4E
SCHEMBL14578437 0.76 ADRA2C (0.62) ADRA2CALDH1A1MAPTKDM4EKMT2A
SCHEMBL1197340 0.76 ADRA2C (0.46) ADRA2CALDH1A1HTR2AHTR2CKMT2A
Hydrochloric Acid SCHEMBL1197059 0.75 ADRA2C (0.45) ADRA2CALDH1A1HTR2AHTR2CKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
EP-2428508-B9 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC (JP) 2016-04-20 EP disclosed
EP-2428508-B1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC (JP) 2015-12-16 EP disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
EP-2428508-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND Astellas Pharma Inc. (JP) 2012-03-14 EP disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ADRA2C 4411/4885ALDH1A1 1554/4885VCP 4556/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ADRA2C 4411/4885ALDH1A1 1554/4885VCP 4556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.